Molecular diagnostics of coronavirus infection

A complete solution for rapid molecular diagnostics of coronavirus infection

With its two complementary platform technologies Amplidiag® and Novodiag®, Mobidiag has the capacity to meet the needs of clinical laboratories and multiple healthcare settings. Currently on the market, these platforms combine high quality and affordable costs, allowing widespread use both in mass screening and on-demand highly targeted or syndromic tests for various infectious diseases. The extremely versatile product offer, the flexibility of the technologies used, and the expertise of the Mobidiag team allow great responsiveness in the development of new products in emergency situations. Rapid molecular diagnostics of coronavirus infection currently offered by Mobidiag in the case of the COVID-19 pandemic are a perfect example.

Since December 2019, COVID-19 has been spreading rapidly throughout the World. You can follow live evolution of the infection on the WHO Coronavirus Disease (COVID-19) Dashboard.

Choose the right coronavirus test based on your needs

 Amplidiag® RESP-4 Amplidiag® COVID-19 Novodiag® COVID-19
Product no. AD-RP4-864 AD-CV-864 NVD-CV-012
Package size 864 tests 864 tests 12 cartridges
Sample type Nasopharyngeal swab Nasopharyngeal swab Nasopharyngeal swab
Technology RT-PCR RT-PCR RT-PCR
Targets SARS-CoV-2 (N gene)
SARS-CoV-2 (E gene)
Influenza A (M gene)
Influenza B (NS gene)
RSV A/B (M gene)		 SARS-CoV-2 (orf1ab gene)
SARS-CoV-2 (N gene)		 SARS-CoV-2 (orf1ab gene)
SARS-CoV-2 (N gene)
Time to results 46 samples in ~3h turnaround time with Amplidiag® Easy platform 55min for amplification
<3h with Amplidiag® Easy platform		 1h20
Availability CE-IVD CE-IVD CE-IVD

Mobidiag offers complementary molecular tests for coronavirus infection diagnostics: targeted panels with Novodiag® COVID-19 and Amplidiag® COVID-19, and a wider, syndromic, panel allowing simultaneous detection of COVID-19, Flu A, Flu B and RSV with Amplidiag® RESP-4 and upcoming Novodiag® RESP-4.

In the Winter season, COVID-19, Flu A, Flu B and RSV infections are highly prevalent. Symptoms following these respiratory infections are overlapping, it is then quite difficult to determine which virus is responsible for a specific symptom to guide diagnostics, and in fine to the relevant treatment. As a result, Mobidiag is now offering Amplidiag® RESP-4 allowing distinction between these 4 key targets: SARS-CoV-2, Influenza A, Influenza B and RSV.

Amplidiag® COVID-19, Novodiag® COVID-19 and Amplidiag® RESP-4 are now CE-IVD. For on-demand testing, we are currently developing Novodiag® RESP-4. Please contact us for more information.

⊗ Please note that Mobidiag tests are not home testing kits. As a result, they are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.

Key Advantages

  • A complete solution for rapid and reliable molecular diagnostics of targeted coronavirus infection (COVID-19) and syndromic for most common respiratory infections (COVID-19, Flu A, Flu B, RSV)
  • Sample quality control to prevent false negative results
  • A test for all sample volumes (by batch or on-demand testing)
  • Self-sufficient in production and securing of raw materials to ensure continuity of testing throughout the complete workflow, from sample collection to results

Dedicated tests

A complete solution for rapid diagnostics of coronavirus infection
Novodiag COVID-19

Amplidiag® RESP-4

CE-IVD. For in vitro diagnostic use.

Amplidiag® RESP-4 test allows the rapid detection of novel coronavirus, Flu A, Flu B and RSV infections. By allowing rapid and reliable detection of the viruses responsible for these infections simultaneously, this qualitative real-time RT-PCR test supports decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.

Contact sales@mobidiag.com or fill in the form below for more information and orders.

    A complete solution for rapid diagnostics of coronavirus infection
    Novodiag COVID-19

    Novodiag® COVID-19

    CE-IVD

    Novodiag® COVID-19 test operates using the on demand rapid ‘sample-in, result-out’ Novodiag® system, allowing the rapid detection of novel coronavirus in 1h20.
    This fully automated solution protects laboratory staff from potential contamination. With its user-friendly nature, the Novodiag® COVID-19 solution can be delivered to high risk and hard to reach areas, as well as decentralized laboratories, without the need for highly trained personnel.
    This qualitative real-time RT-PCR test supports decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.

    Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.

    Contact sales@mobidiag.com or fill in the form below for more information and orders.

      A complete solution for rapid diagnostics of coronavirus infection
      Novodiag COVID-19

      Amplidiag® COVID-19

      CE-IVD

      Amplidiag® COVID-19 test allows the rapid detection of novel coronavirus for large volumes (by batch). By allowing rapid and reliable detection of this novel coronavirus, this qualitative real-time RT-PCR test supports decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.

      Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.

      Contact sales@mobidiag.com or fill in the form below for more information and orders.